Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Bladder Cancer diagnosis Kit Market is driven by rising bladder cancer rates, diagnostic advances, and the focus on early diagnosis for better patient outcomes. Diagnostic businesses, researchers, and physicians must understand these dynamics to develop, commercialize, and use bladder cancer detection kits.
Globally high bladder cancer rates affect dynamics. The rising patient pool due to risk factors including smoking, age, and environmental exposures drives the need for accurate and effective bladder cancer detection technologies.
The market includes biomarker research advances. Identifying and validating bladder cancer biomarkers helps physicians build more accurate and sensitive detection kits for early diagnosis.
Dynamics favor non-invasive diagnostics. Non-invasive bladder cancer screening kits, such as urine-based biomarker or genetic changes testing, are popular due to their ease and reduced patient pain.
The dynamics include liquid biopsy's rise. Low-invasive liquid biopsies can diagnose and monitor bladder cancer early and track treatment responses, altering market dynamics.
Technological integration and point-of-care testing shape dynamics. Rapid and easy-to-use detection tools at the point of care enable bladder cancer diagnosis and decision-making faster.
Standardization and regulatory approvals are dynamics. Regulatory approvals for bladder cancer detection kits are essential, and established methods enhance reliability and repeatability, affecting market acceptance and clinical value.
Market dynamics include patient screening and awareness. Educational and screening programs that raise knowledge of bladder cancer symptoms and early diagnosis enhance patient engagement and demand for detection kits.
Research-development cooperation are dynamics. Collaboration between diagnostic businesses, academic institutes, and healthcare organizations accelerates biomarker discovery and validation, driving innovation and better bladder cancer detection kits.
Cost-effectiveness influences dynamics. Affordable bladder cancer detection kits and their alignment with healthcare budgets affect adoption rates, especially in low-resource locations, underlining the need for cost-effective alternatives for wider usage.
Competition and market entrance techniques play a role. Established players and new entrants force enterprises to use efficient marketing techniques, distinguish their products, and discover niche markets to compete.
Dynamics include AI integration. AI-driven algorithms improve diagnostic accuracy and interpretability, helping healthcare professionals make decisions and advance bladder cancer detection technology.
Global epidemiological differences affect dynamics. Regional bladder cancer incidence rates affect market dynamics, necessitating flexible methods that account for disease frequency, hereditary variables, and healthcare infrastructures.
Dynamics require monitoring after discovery. Bladder cancer detection kits that track treatment response and recurrence help manage patients holistically, impacting the market's responsiveness to clinical demands.
Market dynamics involve ethics and informed consent. Ethics in research and patient communication are critical as diagnostic technologies improve, affecting public trust and adoption of bladder cancer screening kits.
Bladder Cancer Detection Kit Market Highlights:
Global Bladder Cancer Detection Kit Market Overview
Bladder Cancer Detection Kit Market Size was valued at USD 0.111 billion in 2023. The bladder cancer detection kit market industry is projected to grow from USD 0.123 billion in 2024 to USD 0.264 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.94% during the forecast period (2024 - 2032). The key market drivers that are driving the growth include the rising incidence of bladder cancer, greater public knowledge of cancer and its treatments, rising healthcare costs, and rising cigarette and tobacco use.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Bladder Cancer Detection Kit Market Trends
- Growing prevalence of bladder cancer to drive the market growth
The World Cancer Research Fund (WCRF) estimates that roughly 275,000 individuals worldwide are diagnosed with bladder cancer each year, and that 108,000 people worldwide pass away from bladder cancer. Additionally, bladder cancer is the sixth most prevalent disease in men and the 17th most prevalent cancer in women worldwide. Men's bladder cancer incidence rates per 100,000 people were greatest in Greece in 2018 at 40.4%, followed by Lebanon at 40.0% and Denmark at 29.3%. The greatest incidence for females was 9.4 per 100,000 people in Lebanon. The need for a bladder cancer diagnosis is growing as its prevalence and fatality rate are rising globally. As a result, the market CAGR for bladder cancer detection kits is growing as more money is invested in R&D of non-invasive bladder cancer detection technologies.
Over the course of the forecast period, the market is expected to be driven by a number of strategies used by the major market competitors, including product releases and mergers and acquisitions. For example, Merck, known as MSD outside of the United States and Canada, reported a label update for KEYTRUDA, Merck's anti-PD-1 therapy, in first-line advanced urothelial carcinoma (bladder cancer) in the United States in August 2021.
Furthermore, the market for bladder cancer detection kits may experience rapid expansion as a result of rising healthcare costs, expanding burden of bladder cancer, and rising knowledge of bladder diseases and treatments. For instance, the World Bladder Cancer Patient Coalition has declared March 2022 to be "Don't Go Red" Month for Bladder Cancer knowledge in an effort to increase public knowledge of the disease's warning signs and symptoms. Early detection is essential for improving long-term survival and quality of life. Thus, driving the bladder cancer detection kit market revenue.
Bladder Cancer Detection Kit Market Segment Insights
Bladder Cancer Detection Kit Technology Insights
The bladder cancer detection kit market segmentation, based on technology includes Fluorescence In Situ Hybridization (FISH), Enzyme-Linked Immunosorbent Assay (ELISA), and Others. The fluorescence in situ hybridization (FISH) segment dominated the market. To replace cystoscopy in the field of urology, this technology offers a non-invasive diagnostic application. In urology, hybridization is used in in situ fluorescence, a non-invasive diagnostic alternative to cystoscopy. Due to the innovative urine examination technique used in this segment, which uses fluorescent direct-tagged DNA probes to identify genetic abnormalities in urothelial cells found in the urine, this segment is anticipated to take the lead.
Figure 1: Bladder Cancer Detection Kit Market, by Technology, 2023 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Bladder Cancer Detection Kit End Users Insights
The bladder cancer detection kit market segmentation, based on end users, includes Hospitals & Clinics, Diagnostic Centers, Others. The hospitals & clinics category generated the most income. The bladder cancer detection kit market is being driven by innovations in hospital infrastructure across the globe. Investors are utilizing the bladder cancer market to build cancer detection and treatment hospitals. Additionally, the investor constructing hospitals for cancer diagnosis and treatment uses the bladder cancer market.
Bladder Cancer Detection kit Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American bladder cancer detection kit market area will dominate this market. The market for bladder cancer detection kits in North America is driven primarily by the increased prevalence of bladder cancer in the region. The American Cancer Society estimates that in the US in 2020, there will be around 83,730 new cases of bladder cancer and about 17,200 bladder cancer fatalities. Additionally, it is projected that greater government initiatives, improved healthcare infrastructure, and increased R&D spending would all promote the growth of the bladder cancer detection kit market in these regions.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: BLADDER CANCER DETECTION KIT MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe bladder cancer detection kit market accounts for the second-largest market share as the demand for bladder cancer detection is rising due to the increased prevalence and fatality rate in this region. The market for bladder cancer detection kits is also growing as a result of increased investment in R&D of non-invasive bladder cancer detection kits. Further, the German bladder cancer detection kit market held the largest market share, and the UK bladder cancer detection kit market was the fastest growing market in the European region
The Asia-Pacific Bladder cancer detection kit Market is expected to grow at the fastest CAGR from 2024 to 2032. The market for bladder cancer detection kit is expanding as a result of the rising incidence of bladder cancer in the elderly and the growing old population in Asia-Pacific. According to Globocan, the ageing population is the main factor contributing to the rise in bladder cancer occurrences in Japan, where it is estimated that 37,000 new cases are identified each year and 11,000 people die from the disease. Moreover, China’s bladder cancer detection kit market held the largest market share, and the Indian bladder cancer detection kit market was the fastest growing market in the Asia-Pacific region.
Bladder Cancer Detection Kit Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the bladder cancer detection kit market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, bladder cancer detection kit industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the bladder cancer detection kit industry to benefit clients and increase the market sector. In recent years, the bladder cancer detection kit industry has offered some of the most significant advantages to medicine. Major players in the bladder cancer detection kit market attempting to increase market demand by investing in research and development operations include Abbott Laboratories (US), Xiamen Biotime Biotechnology (China), Exact Sciences (US), Hubei Jinjian Biology (China), Nanjing Liming Bio-products Co., Ltd (China), Abingdon Health (UK), Ameritek, Inc. (US), Alfa Scientific Designs (US), NanoEnTek Inc. (South Korea), Diagnosis S.A. (Spain) and Xiamen Boson Biotech Co., Ltd (China).
Abbott Laboratories (Abbott) researches, develops, produces, and markets a wide variety of healthcare goods, including branded generic medications, diagnostic tools, and infant, adolescent, and adult nutritional supplements. The company also sells a range of medical devices, such as those for neuromodulation, electrophysiology, rhythm control, vascular and structural cardiac devices, and heart failure. Additionally, the business sells dietary supplements, minerals, and nutrition goods.
Exact Sciences Corp (Exact Sciences) is a molecular diagnostic firm that focuses on the creation of assays for various cancer kinds. Cologuard test, the company's main product, is a non-invasive stool-based deoxyribonucleic acid (DNA) screening tool authorized by the US FDA for early colorectal cancer and pre-cancer detection. It employs a multi-target strategy to find DNA and hemoglobin biomarkers associated with colorectal cancer. In addition, the business provides Oncotype DX gene expression tests for colon, breast, and prostate cancers, as well as Oncotype DX AR-V7 Nucleus Detect, a liquid-based test intended for advanced-stage prostate cancer.
Key Companies in the bladder cancer detection kit market include
- Abbott Laboratories (US)
- Xiamen Biotime Biotechnology (China)
- Exact Sciences (US)
- Hubei Jinjian Biology (China)
- Nanjing Liming Bio-products Co., Ltd (China)
- Abingdon Health (UK)
- Xiamen Boson Biotech Co., Ltd (China)
- Ameritek, Inc. (US)
- Alfa Scientific Designs (US)
- NanoEnTek Inc. (South Korea)
- Diagnosis S.A. (Spain)
Bladder Cancer Detection Kit Industry Developments
May 2021:To create the non-invasive bladder cancer test URO17, KDx Diagnostics (US) partnered with Cardiff University, the Cardiff and Vale University Health Board, or C&VUHB, and CellPath.
March 2021:For the purpose of commercializing its Urodiag PCR-based diagnostic test for recurring bladder cancer in France, the OncoDiag company, based in France, raised USD 3.0 million.
Bladder Cancer Detection Kit Market Segmentation
Bladder Cancer Detection Kit Technology Outlook
-
Fluorescence In Situ Hybridization (FISH)
-
Enzyme-Linked Immunosorbent Assay (ELISA)
-
Others
Bladder Cancer Detection Kit End User Outlook
-
Hospitals & Clinics
-
Diagnostic Centers
-
Others
Bladder Cancer Detection Kit Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
